# Vertex Pharmaceuticals Incorporated  Share Price Target ‘$458.26’, now 9.7% Upside Potential

- Link: https://www.directorstalkinterviews.com/vertex-pharmaceuticals-incorporated-share-price-target-458.26-now-9.7-upside-potential/4121142876
- Published: 2024-02-16T12:39:11+00:00
- Author: Charlotte Edwards

**Vertex Pharmaceuticals Incorporated** with ticker code (VRTX) have now 23 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The target price High/Low ranges between $578.00 and $325.00 with the average share
target price sitting at $458.26. (at the time of writing). Given that the stocks
previous close was at $417.88 this would indicate that there is a potential upside
of 9.7%. The 50 day moving average now sits at $411.38 and the 200 day moving average
is $365.98. The company has a market capitalization of 109.85B. The stock price 
for the company is currently $426.29 USD

 The potential market cap would be $120,462,340,860 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 30.67, revenue per share of $38.30
and a 13.21% return on assets.

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company
is focused on developing medicines that treat the underlying cause of cystic fibrosis(
CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell 
disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease,
type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs 
in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO(
elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor
and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company
has a pipeline of investigational small molecule, cell and genetic therapies in 
other serious diseases where it has deep insight into causal human biology, including
sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type
1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Share on: